Our highly-skilled team of histotechnicians under the supervision of experienced pathologists perform the male fertility evaluations in rats and mice. The studies are conducted with speed and rigor and the study designs are highly customized to cater to the client product development purposes. We also offer standalone services as required by the clients for performing standalone histopathology or clinical pathology services.
A separate set of additional animals are kept for the vehicle control group for comparison of test item induced changes. The doses are selected based on a dose range finder study or as per the available information on the general toxicity of the test article.
Testing
The test item formulations are prepared in suitable vehicle and typically administered for period of at least 11 weeks before mating, during mating, and until necropsy. Cohabitation is done (ideally 1:1 ratio) with untreated female animals at least for a period of 14 days. The high dose is expected to produce evidence of toxicity whereas the mid and low doses are assigned to determine the dose response effects. Vaginal smears from females are made during the cohabitation for determining the stages of estrous and for the presence of sperm. After confirmation of positive mating, females are separated from the male, body weights recorded during gestation. On gestation day 13 to 15, females are euthanized, gross necropsy is conducted and the number of corpora lutea and the location and status of each implant site (live/dead embryo and early/late resorption) are recorded.
Screening and Evaluation
In males, after a period of one month of successful mating, necropsy is conducted, reproductive organs such as testis, epidydimides, seminal vesicles, and prostrate are collected and preserved for histopathology. Also, semen parameters such as sperm count, sperm motility and sperm viability are evaluated for test item related effects. Serum testosterone levels are also measured. Microscopic examination of testis and epidydimides is carried out for tissue level abnormalities.
Why Aurigene Male Fertility Study and Services?
Highly-skilled team of clinical pathologists
Highly customized study designs
Fast turnaround time
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Toxicology Studies
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Learning Resources
Neoantigen Specific T cells For Cancer Immunotherapy
An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence bypass central thymic tolerance. The success of immune checkpoint blockade...
Read More
Evolution in Pharma Industry and Demand for Integrated CDMO
The pharma industry is evolving and a demand for integrated CDMOs, which can help accelerating innovations, is part of the evolution....
Read More
Physiochemical Characterization Services
Backed by our strong chemistry, we enable “Finger-print” protein structure and functional characterization for proteins from naked proteins to hyperglycosylated or derivatized proteins. ...
Read More
Fixed Dose Combination Formulation
Introduction: A fixed dose combination (FDC) includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage form. Fixed dose combination (FDC) product is expected to provide below advantages: Improved medication compliance by reducing the pill burden of patients. To achieve synergistic activity If combinations include doses of each drug...
Read More
A metal catalyst-free and one-pot synthesis of (3,4- dihydro-2H-benzo[b][1,4]oxazin-2-yl)methanol derivatives in water
2015
A robust and metal catalyst-free method has been developed for the general and green synthesis of racemic (3,4-dihydro-2H-benzo[b][1,4] oxazin-2-yl)methanol derivatives. This simple, mild and practical method involves the reaction of 2-aminophenols with ()-epichlorohydrin in the presence of NaOH in water at room temperature. The reaction features high regioselec...
Read More-
Development and assessment of a Bcs class II - SGLT2 (Sodium Glucose Cotransporter 2) inhibitor drug in the form of solid lipid Nanoparticles by selecting different lipids, co-surfactants, and manufacturing techniques
Drug Delivery System (DDS) has been used successfully in the past few decades to cure illnesses and enhance health because of its improved systemic circulation and ability to regulate the drug's pharmacological action. As pharmacology and pharmacokinetics advanced, the idea of controlled release emerged, demonstrating the significance of drug release in assessing...
Read More -
Development of novel paullone-based PROTACs as anticancer agents
Proteolysis-targeting chimera (PROTACs) represents a promising modality that has gained significant attention for cancer treatment. Using PROTAC technology, we synthesized novel structurally modified paullone-based PROTACs using Cereblon (CRBN) and Von Hippel–Lindau (VHL) E3 ligands....
Read More -
Development and verification of RP-HPLC method for the quantitative determination of Decitabine in tablet dosage formulation
Decitabine is an anti-cancer chemotherapy drug. This article describes method development and method verification of Assay of Decitabine in tablet formulation. A new, precise, rapid, accurate RP-HPLC method has been developed for the estimation of Decitabine in pharmaceutical tablets dosage form. After optimization the good chromatographic separation was achieved...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market